Reviva Pharmaceuticals (NASDAQ:RVPH) Upgraded to “Strong-Buy” at Chardan Capital

Chardan Capital upgraded shares of Reviva Pharmaceuticals (NASDAQ:RVPH) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

Several other research firms have also recently weighed in on RVPH. Benchmark lowered their price objective on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research report on Monday, September 15th. Roth Capital restated a “buy” rating and set a $3.00 price target (down previously from $7.00) on shares of Reviva Pharmaceuticals in a research report on Monday, August 18th. Wall Street Zen raised Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, October 4th. HC Wainwright reduced their price objective on Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. Finally, Maxim Group dropped their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $3.86.

Reviva Pharmaceuticals Stock Down 3.6%

NASDAQ:RVPH opened at $0.48 on Wednesday. The stock has a market cap of $33.28 million, a P/E ratio of -1.04 and a beta of -0.03. The business’s 50-day moving average price is $0.51 and its two-hundred day moving average price is $0.57. Reviva Pharmaceuticals has a twelve month low of $0.25 and a twelve month high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.05. On average, equities research analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. NewEdge Advisors LLC purchased a new stake in Reviva Pharmaceuticals during the 1st quarter valued at about $58,000. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals during the second quarter valued at approximately $31,000. Lido Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals during the third quarter valued at approximately $37,000. Private Advisor Group LLC bought a new position in shares of Reviva Pharmaceuticals in the first quarter worth approximately $191,000. Finally, Geode Capital Management LLC increased its stake in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the period. Institutional investors own 63.18% of the company’s stock.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.